We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+33.77%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$15.6B
AUM Growth
+$3.41B
Cap. Flow
-$91.9M
Cap. Flow %
-0.59%
Top 10 Hldgs %
85.51%
Holding
100
New
7
Increased
16
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$48.4M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$32.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$30.8M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$23.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$11.1M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$115M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$46.5M
3
ARRY
Array Biopharma Inc
ARRY
+$25M
4
SLDB icon
Solid Biosciences
SLDB
+$15.8M
5
NVAX icon
Novavax
NVAX
+$8.68M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
76
Intellia Therapeutics
NTLA
$1.48B
$2.19M 0.01%
128,538
– –
GTHX
77
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.11M 0.01%
127,236
– –
CTMX icon
78
CytomX Therapeutics
CTMX
$690M
$2.09M 0.01%
+194,377
New +$2.87M
HARP
79
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.03M 0.01%
+21,429
New +$2.82M
FOMX
80
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.87M 0.01%
498,189
– –
CNST
81
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$1.81M 0.01%
133,333
– –
GLMD icon
82
Galmed Pharmaceuticals
GLMD
$4.34M
$1.76M 0.01%
1,198
– –
RCUS icon
83
Arcus Biosciences
RCUS
$3.36B
$1.52M 0.01%
121,534
– –
MTEM
84
DELISTED
Molecular Templates, Inc.
MTEM
$1.48M 0.01%
16,949
– –
ADMS
85
DELISTED
Adamas Pharmaceuticals
ADMS
$1.23M 0.01%
172,630
– –
CFRX
86
DELISTED
ContraFect Corporation
CFRX
$1.16M 0.01%
3,643
-5,298
-59% -$2.3M
INFI
87
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.09M 0.01%
580,400
– –
AFMD
88
DELISTED
Affimed
AFMD
$840K 0.01%
20,000
– –
FLGT icon
89
Fulgent Genetics
FLGT
$559M
$744K ﹤0.01%
125,000
– –
AQST icon
90
Aquestive Therapeutics
AQST
$471M
$688K ﹤0.01%
99,600
– –
VIRX
91
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$676K ﹤0.01%
15,905
– –
DVAX
92
DELISTED
Dynavax Technologies
DVAX
$548K ﹤0.01%
75,000
– –
TRIL
93
DELISTED
Trillium Therapeutics Inc.
TRIL
$333K ﹤0.01%
505,262
– –
AIXC
94
AIxCrypto Holdings Inc
AIXC
$14.2M
$244K ﹤0.01%
22
– –
NVAX icon
95
Novavax
NVAX
$1.19B
– –
-235,916
Closed -$8.68M
SLDB icon
96
Solid Biosciences
SLDB
$793M
– –
-39,192
Closed -$15.8M
TARA icon
97
Protara Therapeutics
TARA
$217M
– –
-7,465
Closed -$678K
GNMX
98
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-3,950,419
Closed -$2.77M
1 2 3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, Baker Bros. Advisors held 100 positions worth $15.6B, up 28% from $12.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q1 2019 filing shows 7 new, 16 increased, 6 reduced and 4 closed positions. Its largest new stake was Axsome Therapeutics: 1,200,000 shares worth $17.1M. The largest sale was Genomic Health, Inc., an estimated $115M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q1 2019 buy was Axsome Therapeutics: 1,200,000 shares worth $17.1M.
  • Baker Bros. Advisors added most to Ascendis Pharma A/S in Q1 2019, an estimated $48.4M increase.
  • Baker Bros. Advisors's biggest Q1 2019 reduction was Genomic Health, Inc., cutting an estimated $115M.
  • Baker Bros. Advisors fully exited Solid Biosciences in Q1 2019, selling an estimated $15.8M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $15.6B portfolio in Q1 2019.
  • Baker Bros. Advisors opened 7 new positions and closed 4 in Q1 2019.
  • Baker Bros. Advisors's portfolio value rose 28% quarter-over-quarter to $15.6B.

Based on Baker Bros. Advisors's 13F filing for Q1 2019, filed 15 May 2019.